LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS)

LUng CAncer focuS - Long Term Non-interventional Monitoring of Diagnostic and Treatment Patterns in Patients With Bronchogenic Carcinoma (LUCAS)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04228237

Acronym

LUCAS

Enrollment

2300

Registered

2020-01-14

Start date

2018-06-01

Completion date

2025-05-31

Last updated

2022-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

lung cancer, bronchogenic carcinoma, diagnosis, treatment, non-interventional

Brief summary

Long-term non-interventional monitoring of diagnostics and treatment patterns in newly diagnosed patients in selected pneumology centers in Czech republic.

Detailed description

Diagnosis, treatment and care of patients with bronchogenic carcinoma (BCA) is, as with most other oncological diseases, a complex multidisciplinary process. Due to the lack of information on the speed and success of the initial diagnosis, the use of the necessary laboratory techniques, and the individual therapeutic steps leading to cure or medical failure, the Czech Pneumological and Phtizeology Society (CPPS) decided to carry out long-term non-interventional monitoring of newly diagnosed patients. This monitoring is non-interventional, so the usual diagnostic and therapeutic procedures will be used according to the decision of the physician. All patients with bronchogenic carcinoma diagnosed from June 1, 2018 will be enrolled with up to 60 months of follow-up.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- clinical diagnosis of lung cancer (C34 in MKN classification)

Design outcomes

Primary

Measure	Time frame	Description
Overall survival (OS)	60 months of follow-up	Time from randomization until death from any cause
Progression-free survival (PFS)	any treatment during 60 months of follow-up	Time from randomization until disease progression or death
Time to treatment discontinuation (TTD)	any treatment during 60 months of follow-up	time from starting a medication until treatment discontinuation or death

Secondary

Measure	Time frame	Description
Time to next treatment (TTNT)	60 months of follow-up	Time from end of primary treatment to institution of next therapy

Countries

Czechia

Contacts

Primary ContactJana Alahakoon

jana.alahakoon@oaks.cz+420602350988

Backup ContactJaroslav Duba

jaroslav.duba@oaks.cz+420606613224

Outcome results